文献速递银屑病与炎症性皮肤病

AURIEL-PsO:MSB11022 与参照阿达木单抗治疗中重度斑块状银屑病的 III 期等效性试验

AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
PubMed 文献 · Br J Dermatol · 2019-09-26

AURIEL-PsO 是一项双盲随机对照等效性试验,将 443 例中重度慢性斑块状银屑病患者按 1:1 随机分配至 MSB11022 或参照阿达木单抗组。研究显示两药在疗效、安全性和免疫原性方面等效,且第 16 周从参照药切换至 MSB11022 未影响上述结局。

要点

  • 两药治疗中出现的不良事件发生率至试验结束无显著差异,未见新安全信号
  • 第 16 周切换至 MSB11022 后,至观察期末安全性和免疫原性无临床意义差异

核心结论

  • MSB11022 与参照阿达木单抗在治疗中重度慢性斑块状银屑病中证实治疗等效。
  • AURIEL-PsO 研究为两产品在疗效、安全性和免疫原性方面的相似性提供了证据。

研究设计与样本

  • AURIEL-PsO 为双盲随机对照等效性试验,中重度慢性斑块状银屑病患者按 1:1 随机分配至 MSB11022 或参照阿达木单抗组。
  • 共随机分配 443 例患者。
  • 主要终点为第 16 周 PASI 75 应答率,预设等效区间为 ±18%。
  • 第 16 周 PASI 改善 ≥50% 的患者可进入双盲扩展期:MSB11022 组继续治疗,参照阿达木单抗组按 1:1 再随机分配至继续参照药或切换至 MSB11022。
  • 疗效和免疫原性观察至第 52 周,安全性观察至第 54 周和第 66 周。

主要发现

  • 至试验结束,两治疗组治疗中出现的不良事件发生率无显著差异,未观察到新的安全信号。
  • 第 16 周治疗切换后,至观察期末两治疗组在安全性和免疫原性方面无临床意义差异。

关键数值与推荐

  • 第 16 周 PASI 改善 ≥50% 的患者符合进入双盲扩展期条件。
  • 疗效和免疫原性随访至第 52 周,安全性随访至第 54 周和第 66 周。

临床怎么用

  • MSB11022 可作为参照阿达木单抗的生物类似药用于中重度慢性斑块状银屑病治疗。
  • 从参照阿达木单抗切换至 MSB11022 未影响疗效、安全性和免疫原性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MSB11022 is a proposed adalimumab biosimilar. OBJECTIVES: To compare the efficacy, safety and immunogenicity of MSB11022 with reference adalimumab. METHODS: AURIEL-PsO was a double-blind randomized controlled equivalence trial, in which patients with moderate-to-severe chronic plaque-type psoriasis were randomized 1 : 1 to MSB11022 or reference adalimumab. The primary end point was ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) at week 16, with a prespecified equivalence interval of ± 18%. Patients with a ≥50% improvement in PASI at week 16 were eligible to enter a double-blind extension period: patients receiving MSB11022 continued treatment, and patients receiving reference adalimumab were rerandomized 1 : 1 either to continue reference adalimumab or to switch to MSB11022. Other efficacy end points and safety, immunogenicity and pharmacokinetic parameters were evaluated at scheduled visits up to weeks 52 (efficacy and immunogenicity), 54 and 66 (safety). RESULTS: In total, 443 patients were randomized. The difference in PASI 75 response rates at week 16 between the treatment arms was -1·9%, and the 95% confidence interval (-7·8% to 4·1%) was within the prespecified equivalence interval. No notable difference in the incidence of treatment-emergent adverse events was observed between treatment arms up to the end of the trial, and no new safety signals were observed. Following treatment switch at week 16, no clinically meaningful differences in safety or immunogenicity were seen between treatment arms through to the end of the observation period. CONCLUSIONS: Therapeutic equivalence between MSB11022 and reference adalimumab was demonstrated. AURIEL-PsO provides evidence to support the similarity of both products with regard to efficacy, safety and immunogenicity. What's already known about this topic? Adalimumab is a fully human antitumour necrosis factor-α monoclonal antibody, indicated for the treatment of multiple inflammatory disorders, including psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel diseases and ankylosing spondylitis. MSB11022 is a proposed adalimumab biosimilar that has shown structural and functional similarity to the reference product in an extensive analytical comparability exercise. MSB11022 has demonstrated bioequivalence and comparable safety and immunogenicity profiles in a phase I study in healthy volunteers. What does this study add? This phase III study confirmed equivalent efficacy for MSB11022 and reference adalimumab in patients without any immunomodulation comedication in moderate-to-severe chronic plaque-type psoriasis at week 16. The efficacy, safety and immunogenicity of MSB11022 and reference adalimumab were similar over the respective observation periods (week 52 for efficacy and immunogenicity, week 66 for safety). A switch from reference adalimumab to MSB11022 at week 16 did not impact efficacy, safety or immunogenicity.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hercogová J, Papp KA, Chyrok V, et al. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2019. PMID: 31206593. doi:10.1111/bjd.18220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。